# US 2014/0155363 A1 · Process and intermediates for the preparation of abiraterone acetate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155363 A1
- Document ID: US20140155363A1
- Status: Published application
- Kind: A1
- Application number: 14/176,463
- Filed: 2014-02-10
- Published: 2014-06-05
- Earliest claimed: 2012-07-25
- Assignees: Mapi Pharma Ltd.
- Applicants: Mapi Pharma Ltd.
- Inventors: Ehud MAROM; Shai RUBNOV; Michael MIZHIRITSKII
- Web page: https://patentgrep.com/patent/US20140155363A1

## CPC

- C07J 43/003: {not condensed}
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61P 35/00: Antineoplastic agents
- C07J 43/00: Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J 51/00: Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a process for the synthesis of (3beta)17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates in such processes.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A process for the preparation of (3β)17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate represented by the structure of formula (1), and salts thereof
the process comprising the steps of:
a) coupling a protected dehydroepiandrosterone (10) with a pyridinyl derivative (11) to form a pyridinyl hydroxy derivative (12):
wherein
PG is a hydroxyl protecting group; and
M is selected from the group consisting of Li, Na, K, MgX, ZnX, CdX, Si(R)3, Ge(R)3 and Sn(R3); wherein X is a halogen and R is a substituted or unsubstituted alkyl, cycloalkyl, alkylaryl or aryl;
b) converting compound (12) to (17-pyridin-3-yl)-androsta-5,16-diene (13):
and
c) transforming compound (13) into (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol (Abiraterone acetate) (1).

### Claim 22 (depends on 21)

The process according to claim 21, wherein the hydroxyl protecting group PG is selected from the group consisting of acetate (Ac), benzyl (Bzl), Si(Ra)3, tetrahydropyranyl (THP) and trityl (Trt), wherein Ra is a substituted or unsubstituted alkyl, cycloalkyl, alkylaryl or aryl.

### Claim 23 (depends on 21)

The process according to claim 21, wherein M is Li or MgX, wherein X is Cl, Br or I.

### Claim 24 (depends on 21)

The process according to claim 21, wherein step (a) is carried out by reacting compound (10) with 3-Py-Li in an organic solvent at a temperature of about −70° C. to about 0° C., in the absence or presence of one or more additives.

### Claim 25 (depends on 24)

The process according to claim 24, wherein step (a) is carried out in the presence of an additive selected from the group consisting of: (i) an amine; (ii) an amide; (iii) an inorganic salt; (iv) a rare earth element salt; and (v) salt mixtures or complex salts.

### Claim 26 (depends on 25)

The process according to claim 25, wherein
(i) the amine is N,N′-tetramethylethylenediamine;
(ii) the amide is 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU);
(iii) the inorganic salt is selected from lithium chloride, lithium perchlorate, cadmium chloride, magnesium chloride, zinc chloride and ferric chloride;
(iv) the rare earth element salt is a lanthanide salt selected from lathanium chloride and cerium chloride;
(v) the salt mixtures of complex salts are selected from YCl3.2LiCl, CeCl3.2LiCl, NdCl3.2LiCl, PrCl3.2LiCl, DyCl3.2LiCl and ErCl3.2LiCl.

### Claim 27 (depends on 26)

The process according to claim 26, wherein the additive is lithium chloride, zinc chloride, or LaCl3.2LiCl.

### Claim 28 (depends on 21)

The process according to claim 21, wherein step (a) is carried out by reacting compound (10) with 3-Py-MgX in an organic solvent at about room temperature to about reflux in the absence or presence of an additive.

### Claim 29 (depends on 28)

The process according to claim 28, wherein step (a) is carried out in the presence of an additive selected from the group consisting of: lithium chloride, cadmium chloride, magnesium chloride, zinc chloride, a rare earth element salt, and salt mixtures of any of said additives.

### Claim 30 (depends on 29)

The process according to claim 29, wherein the additive is present from about 0.01 to about 5.0 equivalents relative to the 3-Py-MgX.

### Claim 31 (depends on 21)

The process according to claim 21, wherein step (b) is carried out in the presence of a strong acid in an organic solvent at an elevated temperature of about 40° C. to about reflux.

### Claim 32 (depends on 31)

The process according to claim 31, wherein the acid is an inorganic or organic acid selected from the group consisting of hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, para-toluenesulfonic acid, methanesulfonic acid, tungstic acid, and polymeric acid resins.

### Claim 33 (depends on 21)

The process according to claim 21, wherein step (b) is carried out by conversion of compound (12) to (13) directly.

### Claim 34 (depends on 21)

The process according to claim 21, wherein step (b) is carried out by conversion of the hydroxyl in compound (12) to a leaving group to generate compound (14), followed by converting compound (14) to compound (13):
wherein LG is a leaving group selected from a halogen or a sulfonate ester group of the formula —OSO2Rb wherein Rb is a substituted or unsubstituted alkyl, cycloalkyl, alkylaryl or aryl.

### Claim 35 (depends on 21)

The process according to claim 21, further comprising the step of converting Abiraterone acetate into a salt thereof with a pharmaceutically acceptable acid.

### Claim 36 (depends on 21)

A compound represented by the structure of formula (1) (Abiraterone acetate), which is prepared in accordance with the process according claim 21.

### Claim 37 (depends on 21)

A method of treating metastatic castration-resistant prostate cancer (CRPC), the method comprising the step of administering a subject in need thereof the compound of formula (1) (Abiraterone acetate) which is manufactured in accordance with the process of claim 21.

### Claim 38

A process for preparing a compound represented by the structure of formula (A), comprising the step of coupling a ketone or an aldehyde represented by the structure of formula (C) with a compound of formula (11) to a form pyridinyl-tertiary alcohol (A)
wherein
R1 and R2 are each H or an unsubstituted or substituted alkyl, cycloalkyl, alkylaryl or aryl; and
M is selected from the group consisting of Li, Na, K, MgX, ZnX, CdX, Si(R)3, Ge(R)3 and Sn(R)3; wherein X is a halogen and R is a substituted or unsubstituted alkyl, cycloalkyl, alkylaryl or aryl.

### Claim 39

A compound represented by the structure of formula (12), or a salt thereof:
wherein PG is a hydroxyl protecting group.

### Claim 40

A compound represented by the structure of formula (14):
wherein
PG is a hydroxyl protecting group; and
LG is a leaving group selected from a halogen or a sulfonate ester group of the formula —OSO2Rb wherein Rb is a substituted or unsubstituted alkyl, cycloalkyl, alkylaryl or aryl.

### Claim 41 (depends on 40)

The compound according to claim 40, wherein the hydroxyl protecting group PG is selected from the group consisting of acetate (Ac), benzyl (Bzl), Si(Ra)3, tetrahydropyranyl (THP) and trityl (Trt), wherein Ra is a substituted or unsubstituted alkyl, cycloalkyl, alkylaryl or aryl.
